相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patients with major depressive disorder have lower cerebral serotonin 4 receptor binding than healthy controls
K. Koehler-Forsberg et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting
Chad A. Bousman et al.
PHARMACOGENETICS AND GENOMICS (2017)
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
L. V. Kalman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels
Natchaya Vanwong et al.
DRUG METABOLISM AND PHARMACOKINETICS (2016)
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes A GeT-RM Collaborative Project
Victoria M. Pratt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation
Joel G. Winner et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Clinical Association Between Pharmacogenomics and Adverse Drug Reactions
Zhi-Wei Zhou et al.
DRUGS (2015)
A global reference for human genetic variation
David M. Altshuler et al.
NATURE (2015)
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes
C. A. Altar et al.
PHARMACOGENOMICS JOURNAL (2015)
HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis
Sandeep Grover et al.
PHARMACOGENETICS AND GENOMICS (2014)
Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders
Junji Saruwatari et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2014)
HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children
U. Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
Daniel K. Hall-Flavin et al.
PHARMACOGENETICS AND GENOMICS (2013)
Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels
Daniela J. Conrado et al.
PHARMACOGENOMICS (2013)
Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression
J. Winner et al.
TRANSLATIONAL PSYCHIATRY (2013)
Early switch strategy in patients with major depressive disorder
Chi-Un Pae et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Using a pharmacogenomic algorithm to guide the treatment of depression
D. K. Hall-Flavin et al.
TRANSLATIONAL PSYCHIATRY (2012)
A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC
Paul I. W. de Bakker et al.
NATURE GENETICS (2006)
The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients
M Ueda et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
分享论文
